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Abstract
Background & aims
To determine the prognostic potential of classic and novel serologic antibodies regarding
unfavorable disease course in a prospective ulcerative colitis (UC) patient cohort, since few
and conflicting data are available in the literature regarding this matter.
Methods
187 consecutive patients were studied prospectively (median follow-up: 135 months) from a
single referral IBD center in Hungary. Sera were tested for different IgA/IgG type autoanti-
bodies (anti-neutrophil cytoplasmic [ANCA], anti-DNA-bound-lactoferrin [anti-LFS], anti-
goblet cell [anti-GAB] and anti-pancreatic [PAB: anti-CUZD1 and anti-GP2)]) by indirect
immunofluorescence technique and for anti-microbial (anti-Saccharomyces cerevisiae
[ASCA] IgG/IgA and anti-OMP Plus™ IgA) antibodies by enzyme-linked immunosorbent
assays.
Results
A total of 73.6%, 62.4% and 11.2% of UC patients were positive for IgA/IgG type of atypical
perinuclear-ANCA, anti-LFS and anti-GAB, respectively. Occurrences of PABs were 9.6%,
while ASCA IgA/IgG and anti-OMP IgA were 17.6% and 19.8%, respectively. Antibody sta-
tus was stable over time. IgA type PABs were more prevalent in patients with primary scle-
rosing cholangitis (37.5% vs. 4.7% for anti-CUZD1 and 12.5% vs. 0% for anti-GP2, p<0.001
for both). IgA type ASCA and anti-CUZD1 antibodies were associated with higher risk of
requirement for long-term immunosuppressant therapy in Kaplan-Meier analysis (pLogRank
<0.01 for both). However, in multivariate Cox-regression analysis only ASCA IgA (HR: 2.74,
95%CI: 1.46–5.14, p<0.01) remained independent predictor. UC-related hospitalization due
to disease activity was only associated with multiple antibody positivity (for 3 or more; HR
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2.03 [95% CI: 1.16–3.56]; p = 0.013). None of the individual antibodies or their combination
was associated with the risk of development of extensive disease or colectomy.
Conclusion
Even with low prevalence rates, present study gives further evidence to the role of certain
antibodies as markers for distinct phenotype and disease outcome in UC. Considering the
result of the multivariate analysis the novel antibodies investigated do not seem to be asso-
ciated with poor clinical outcome in UC, only a classic antibody, IgA subtype ASCA
remained an independent predictor of long-term immunosuppressive therapy.
Introduction
Enhanced antibody formation in the serum is a well-known feature of inflammatory bowel
diseases (IBD). A wide range of anti-microbial and autoantibodies have been reported to be
associated with either Crohn’s disease (CD) or ulcerative colitis (UC) [1]. Anti-microbial anti-
bodies are formed against different surface carbohydrate (glycans [2]) or protein antigens of
various gut microbes [3], while autoantibodies are directed against host proteins. Currently,
the most relevant anti-microbial antibody is the ASCA (anti-Saccharomyces cerevisiae anti-
body), while the major autoantibody is the ANCA (anti-neutrophil cytoplasmic antibody).
The panel of serologic antibodies, however, has continuously been expanding [1] calling for
clarification of whether these new markers are superior or add value to the conventional mark-
ers. Existence of serologic markers might be considered as a reflection of the enhanced micro-
bial challenge to the gut [4, 5] due to a disturbed gut innate immune system that triggers an
exaggerated adaptive immune response. These serologic antibodies may also be actively
involved in the pathophysiology of gut inflammation in IBD [6, 7].
Serologic antibodies play a potential role in providing an insight into the etiopathogenesis
of IBD, establishing the diagnosis of IBD and to differentiating CD from UC. Currently, their
most fascinating and relevant potential is to stratify the risk of evolving a complicated disease
course that might dictate earlier more aggressive treatment [8]. This latter issue was extensively
studied in CD [1], however, data are few and conflicting regarding the association of serologic
markers to the disease course [9–14], medical treatment and response to therapy [9, 10, 13] in
patients with UC, especially with the newly discovered antibodies. Thus a comprehensive eval-
uation of a panel of serologic antibodies in a large prospectively followed UC cohort is
required.
The aims of the present study were to investigate: (1) long-term stability of a panel of sero-
logic antibodies comprising classic and newly discovered markers, (2) associations between
the presence of antibodies and the clinical phenotype of the disease, (3) prognostic potential of
these antibodies with regards to the long-term disease course in a large prospective referral
adult UC cohort.
Materials and methods
Patient population
We performed a cohort study among adult UC patients in a Hungarian tertiary IBD referral
center (Gastroenterology Department of Institute of Medicine, University of Debrecen). The
baseline clinical data regarding this cohort overlap with our previous studies [15, 16], however
UC serology
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hereby we present an extended follow up time with nearly 2 and a half years and re-evaluation
of the outcomes. We used the same step by step thorough statistical evaluations; therefore the
text appeared to reproduce information already reported in detail elsewhere.
Diagnosis of IBD was based on the Lennard–Jones criteria [17]. Detailed clinical pheno-
types were captured at inclusion. Clinical data were determined by thorough review of
patients’ medical records, which had been collected in a uniform format described in detail in
our previous studies [15, 16]. Medical records that documented age at presentation, disease
extent [18], presence of extraintestinal manifestations [EIM] and familial IBD, smoking habits,
medication use, UC-related hospitalization due to disease activity, development of extensive
disease (from E1/E2 to E3) and need for colectomy, were retrospectively analyzed for the
period prior to the prospective follow-up. At enrolment, clinical disease activity was calculated
according to the partial Mayo score [19]. Mayo score 3 was defined as a state of remission
and>4 as a state of active disease. Endoscopic activity was determined according to the endo-
scopic component of the Mayo score [20]. A state of active disease was defined as1 points
according to endoscopic partial Mayo score.
Phenotypical characterization of IBD patients during prospective follow-
up
183 of 187 UC patients were available to be enrolled into a prospective follow-up study, where
the treating IBD physicians registered laboratory data, endoscopic and imaging findings, dis-
ease activity, medical treatment, date of UC-related hospitalization, development of extensive
disease (from E1/E2 to E3) and colectomy during regular and extraordinary outpatient follow-
up visits and inpatient stays. Maximal disease extent (proctitis, left-sided colitis, and extensive
colitis) [18], observed during endoscopic follow-up was also registered. UC-related hospitali-
zation was defined as any admission for the treatment of UC disease activity. Colectomy per-
formed for medically refractory disease was considered in analyses. In Hungary, a follow-up
visit is usually scheduled for every 6 months at a specialized gastroenterology center (the actual
interval varies between 3–6 months). The treatment algorithms, both the medical and the sur-
gical, are harmonized and followed the ECCO guidelines. Need for colectomy and its timing is
a consistent multidisciplinary decision with the collaboration of the gastroenterologist, radiol-
ogist, and surgeon [21–23]. Collected data were transferred and stored in a database for analy-
sis. In May 31, 2015, all patients’ charts and database were reviewed and updated for the data
points mentioned above. Follow-up for a particular patient was terminated if there was no fur-
ther record available.
The treating physicians were aware of the antibody seropositivity of the patients, but did
not incorporate them into their regular clinical decision making (e.g. treatment choices),
except only in case of selected differential diagnostic problems (using ASCA and pANCA sta-
tus to distinguish CD, especially patients with only colonic localization [L2 according to Mon-
treal classification], from UC), alongside with ECCO guidelines on this matter [1, 24, 25].
Serologic antibody determination
Sera obtained at enrolment were separated from venous whole blood and stored at -80˚C.
Atypical P-ANCA, anti-LFS, anti-goblet, anti-GP2 and anti-CUZD1 IgA and IgG were
detected using cell-based indirect immunofluorescence tests (IIFT) [Morbus-Crohn Mosaic 1,
Euroimmun Medizinische Labordiagnostika AG, Lu¨beck, Germany] in a manner previously
described [15]. A specific fluorescence at a dilution of 1:32 or higher was considered positive
for P-ANCA and anti-LFS and 1:10 or higher for anti-goblet, anti-CUZD1 and anti- GP2
UC serology
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antibodies. The interpretation of ANCA pattern was based on the behavior of the specimens
on ethanol- and formalin- fixed slides according to previously reported [26].
Both serum IgG and IgA levels of anti-Saccharomyces cerevisiae antibodies (ASCA) and
anti-OMP Plus™antibodies were evaluated by enzyme-linked immunosorbent assay (ELISA)
separately [QUANTA Lite1, Inova Diagnostics, San Diego, CA]. The results are presented as
arbitrary units with a cut-off value for positivity of 25 Units.
Sera were documented both, in absolute values and in frequency of positivity. Additionally,
in case of each antibody, a highest quartile was defined by titers above laboratory cut-off values
belonging to the Q3-Q4 range (75th-100th percentiles). We used these in the quantitative analy-
sis of associations between antibody titers and poor disease outcomes.
To evaluate the stability of various serologic antibodies [status of positive or negative for a
respective antibody], we analyzed samples from the same patient over various arbitrary time-
points during the disease course. At least two serum samples were taken from each of the
majority of UC patients [n = 106] and re-tested for all different serologic antibodies.
Statistical analysis
Variables were tested for normality using Shapiro Wilk’s W test. Continuous variables were
summarized as means (standard deviation [SD]) or as medians (interquartile range [IQR])
according to their homogeneity. To evaluate differences within patient subgroups, the follow-
ing statistical methods were used. Categorical variables were compared with Fisher’s exact test
or χ2 test with Yates correction, linear-by-linear association, as appropriate. Continuous vari-
ables were compared with Student’s t test, one-way analysis of variance [ANOVA], or Mann-
Whitney’s U test or Kruskal-Wallis H test with post hoc analysis [Dunn’s multiple comparison
test]. Kaplan-Meier survival curves were plotted for analyzing the association between categor-
ical clinical variables or serologic antibodies and unfavorable disease outcomes during follow-
up with LogRank testing or Cox-regression analysis in the time-dependent models. Associa-
tions are given as odds ratio [OR] and hazard ratio [HR] with a 95% confidence intervals [CI].
A 2-sided probability value < 0.05 was considered to be statistically significant. A post-hoc
power analysis was performed in Stata (v13.0) with a detailed description of the evaluation and
results provided in the Supplementary Material (S1 File). For statistical analysis, GraphPad
Prism 6 [San Diego, CA] and SPSS 22.0 [SPSS, Chicago, IL], Stata (v13.0) [StataCorp. 2013.
Stata Statistical Software: Release 13. College Station, TX: StataCorp LP] programs were used.
Ethical considerations
The regional (the Institutional Review Board of the University of Debrecen) and national (the
Hungarian National Review Board) committee (DEOEC RKEB/IKEB 3515–2011, 3880/2012/
EKU [59/PI/2012]) for research ethics approved the study protocol. Each patient was informed
of the nature of the study and signed an informed consent form.
Results
Clinical characteristics of UC patients
In all, 187 well-characterized, unrelated, consecutive UC patients with a complete clinical
follow-up (age range at presentation: 8–68 years, at first sampling: 17–85 years) seen at our
Outpatient Clinic were enrolled between January 1, 2005 and June 1, 2010. The clinical charac-
teristics of the patients at time of inclusion and sample procurement are presented in Table 1.
Median follow-up from the diagnosis months 135 [IQR]: 84–213.
UC serology
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Frequency of serologic antibodies
A total of 73.6%, 62.4% and 11.2% of UC patients were positive for IgA/IgG type of atypical
P-ANCA, anti-LFS and anti-GAB, respectively. Both types of PAB occurred as well, 9% of the
patients were positive for anti-CUZD1 ( anti-rPAg1) and 0.6% for anti-GP2 ( anti-rPAg2)
IgA/IgG. ASCA IgA/IgG and anti-OMP IgA positivity was 17.6% and 19.8%, respectively. Fre-
quencies of the different antibodies in UC patients are summarized in Table 2.
Table 1. Clinical characteristics of patients with ulcerative colitis (UC).
UC
(n = 187)
Male/female (n) 86/101
Age at presentation (years) 33 (23–43)
Familial IBD1 6 (3.2%)
Disease extent at diagnosis1
E1 30 (16.0%)
E2 104 (55.6%)
E3 53 (28.3%)
Primary sclerosing cholangitis 8 (4.3%)
Extraintestinal manifestations (EIM)
Arthritis 26 (13.9%)
Skin 16 (8.6%)
Ocular 12 (6.4%)
Smoking habits1
never 167 (89.3%)
yes 18 (9.6%)
past 2 (1.1%)
Disease activity at study enrollment1
Inactive partial Mayo 3 135 (72.2%)
Active partial Mayo> 4 52 (27.8%)
Follow-up (months) from
diagnosis☐ 135 (84–213)
sampling 78 (51–102)
Maximal disease extent1,⃠
E1 23 (12.8%)
E2 97 (53.9%)
E3 60 (33.3%)
UC related hospitalization1 64 (35.0%)
Exposure of medication and surgery during follow-up
Steroid use1 117 (63.9%)
Steroid refractory1 11 (7.6%)
Azathioprine use1 70 (38.3%)
Biological use1 25 (13.4%)
Colectomy1 11 (6.0%)
1n (%),
: median (IQR)
☐: 183 UC patients had follow-up from the diagnosis
⃠180 data were available
Disease extent: E1: proctitis, E2: left-sided colitis, E3: extensive colitis
https://doi.org/10.1371/journal.pone.0194166.t001
UC serology
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Stability of serologic antibodies
Median time between sample procurements was 21.1 months [IQR, 11.2–41.1]. Interestingly,
the status of most serologic antibodies was very stable over time regarding both IgA and IgG
subtypes, with only 10% of cases changing their antibody status over time. Atypical P-
ANCA and anti-LFS antibodies, showed somewhat higher variation up to 23% of cases. Stabil-
ity data of various serologic antibodies are summarized in Table 3. In case of anti-OMP IgA
data regarding stability was available in only 23 UC patients, 82.6% of them were stable nega-
tive, while 17.4% appeared to be stable positive. None of them changed their antibody status
over time.
In addition, no association was detected between the status of various serologic antibodies
and the clinical or endoscopic disease activity [actual partial or endoscopic part of Mayo] at
the time of sample procurement (data available in the public repository “Figshare” with the fol-
lowing related doi number: 10.6084/m9.figshare.4765102).
Associations of serologic antibody profiles to clinical phenotype of the
disease
No significant association was demonstrated between presence of serologic antibodies and
gender, younger age at diagnosis (age 16 years), or colitis extent.
Presence of certain antibodies was less prevalent in patients with EIM: anti-LFS antibodies
in ocular diseases (20.0% vs. 64.9%, p = 0.004 for IgG subtype), while atypical P-ANCA (45.8%
vs. 74.0%, p = 0.005for IgG subtype) and anti-LFS antibodies (0.0% vs. 17.5%, p = 0.026 for IgA
Table 2. Serologic antibodies in patients with ulcerative colitis (UC).
Serologic antibodies Type Positive Cut-off N UC, n(%)
Atypical P-ANCA Either 1:32 178 131 (73.6%)
IgG 125 (70.2%)
IgA 72 (40.4%)
Anti-LFS Either 1:32 178 111 (62.4%)
IgG 111 (62.4%)
IgA 27 (15.2%)
Anti-goblet cell Either 1:10 178 20 (11.2%)
IgG 11 (6.2%)
IgA 11 (6.2%)
Anti-CUZD1
( rPAg1)
Either 1:10 178 16 (9.0%)
IgG 12 (6.7%)
IgA 11 (6.2%)
Anti-GP2
( rPAg2)
Either 1:10 178 1 (0.6%)
IgG 0 (0.0%)
IgA 1 (0.6%)
ASCA Either 25 U/ml 187 33 (17.6%)
IgG 21 (11.2%)
IgA 21 (11.2%)
Anti-OMP IgA 25 U/ml 182 36 (19.8%)
ASCA: anti-Saccharomyces cerevisiae antibody, LFS: lactoferrin, CUZD1: CUB and zona pellucida-like domains 1,
GP2: glycoprotein 2, P-ANCA: perinuclear anti-neutrophil cytoplasmic antibodies
https://doi.org/10.1371/journal.pone.0194166.t002
UC serology
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subtype) in arthritis. While other antibodies were more prevalent in patients with EIM: such as
GAB in ocular diseases (40.0% vs. 9.5%, p = 0.016for IgG/IgA subtype). None of the antibodies
was, however, associated with cutaneous manifestation of the disease.
IgA but not IgG types PABs were more prevalent in patients with PSC (37.5% vs. 4.7% for
anti-CUZD1 and 12.5% vs. 0% for anti-GP2, p<0.001 for both).
Lastly, presence of anti-LFS antibodies was negatively associated with current smoking sta-
tus (No vs. Yes, 65.6% vs. 33.3%, p = 0.01 for IgA/IgG subtype) as well.
All of these data are presented in Table 4.
Significance of serologic antibodies in the risk of unfavorable disease
course
In Kaplan-Meier analysis, the presence of certain antibodies was associated with an increased
cumulative probability of study-endpoint events compared to the absence of these antibodies
(summarized in Table 5 and S1 Table).
Further analyzing the quantitative associations with unfavorable disease outcomes, we did
not find the use of highest quartiles as cut-off values superior compared to the original ones.
Cumulative probability of UC-related hospitalization was significantly higher in anti-
CUZD1 IgG (78.6% vs. 28.8%, pLogRank = 0.031), but not in IgA positive cases at 135 months of
the follow-up period. In case of the latter antibody, evaluating at higher titer as a cut-off point
(1:1000; HRCUZD1IgA: 1.91 [95% CI: 0.69–5.30]; p = 0.214), similar result was found to that
one obtained at lower cut-off value (1:10; HRCUZD1IgA: 2.16 [95% CI: 0.91–5.10]; p = 0.077).
At the same time, cumulative probability of need for long-term immunosuppressant ther-
apy with azathioprine [AZA] was significantly higher either in anti-CUZD1 IgG (78.1% vs.
36.2%, pLogRank = 0.008) or IgA positive cases (84.1% vs. 36.8%, pLogRank = 0.005) as compared
to antibody negative ones. The risk of need for long-term immunosuppressant therapy did not
differ according to the extent of anti-CUZD1 IgA antibody positivity (HRCUZD1IgA: 2.53 [95%
CI: 1.09–5.91]; p = 0.032 for titer of1:1000 and HRCUZD1IgA: 2.78 [95% CI: 1.31–5.89];
p = 0.007 for titer of1:10). The presence of IgA as well as IgG type CUZD1 was associated
with the need of colectomy, however with only borderline significance without clinically
Table 3. Stability of serologic marker status over time in patients with ulcerative colitis (UC) during the disease course.
Serologic antibodies Type N Stable
negative, n(%)
Stable positive, n(%) Negative to Positive, n(%) Positive to Negative, n(%)
Atypical P-ANCA IgG 104 19 (18.3) 70 (67.3) 10 (9.6) 5 (4.8)
IgA 104 46 (44.2) 34 (32.7) 9 (8.7) 15 (14.4)
Anti-LFS IgG 104 26 (25.0) 54 (51.9) 14 (13.5) 10 (9.6)
IgA 104 81 (77.9) 9 (8.7) 8 (7.7) 6 (5.8)
Anti-goblet cell IgG 103 94 (91.3) 4 (3.9) 1 (1.0) 4 (3.9)
IgA 103 93 (93.3) 6 (5.8) 0 (0.0) 4 (3.9)
Anti-CUZD1 ( rPAg1) IgG 104 96 (92.3) 5 (4.8) 0 (0.0) 3 (2.9)
IgA 104 95 (91.3) 2 (1.9) 2 (1.9) 5 (4.8)
Anti-GP2 ( rPAg2) IgG 104 103 (99.0) 0 (0.0) 1 (1.0) 0 (0.0)
IgA 104 102 (98.1) 0 (0.0) 2 (1.9) 0 (0.0)
ASCA IgG 106 83 (78.3) 11 (10.4) 11 (10.4) 1 (0.9)
IgA 106 86 (81.2) 9 (8.5) 8 (7.5) 3 (2.8)
ASCA: anti-Saccharomyces cerevisiae antibody, LFS: lactoferrin, CUZD1: CUB and zona pellucida-like domains 1,GP2: glycoprotein 2, P-ANCA: perinuclear anti-
neutrophil cytoplasmic antibodies
https://doi.org/10.1371/journal.pone.0194166.t003
UC serology
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relevant cumulative probability differences (0.0 vs. 5.5%; pLogRank = 0.026 and pLogRank = 0.027,
respectively). Comparing higher serum antibody titers (1:1000; HRCUZD1IgA: 5.58 [95% CI:
1.15–27.04]; p = 0.033) with lower ones (1:10; HRCUZD1IgA: 5.01 [95% CI: 1.03–24.28];
p = 0.045) carried the same risk.
Cumulative probability of UC-related hospitalization did not differ according to IgA or
IgG ASCA status. The use of higher cut-off value of IgA type ASCA (47 U; HRASCAIgA: 2.34
[95% CI: 0.85–6.50]; p = 0.102) in the analysis yielded similar results to lower titer (25 U;
Table 5. Univariate and multivariate Cox-regression analysis evaluating association between clinical and serologic variables and the study end-point events (ulcera-
tive colitis-related hospitalization and need for immunosuppressant therapy).
. . . UC Related Hospitalisation Need for Long-Term Immunosupressant Therapy
. . . . univariate analysis mulivariate analysis univariate analysis mulivariate analysis
. . n of
subject
CP of event
(%)
pLogRank HR (95% CI) p-
value
HR (95% CI) p-
value
CP of event
(%)
pLogRank HR (95%
CI)
p-value HR (95%
CI)
p-value
Overall population . 183 32.9 . . . . . 38.3
Clinical factors . . . . . . . .
Age A1 10 40.0 0.092 2.0 (0.84–
4.77)
0.118 30.0 0.672 1.21 (0.38–
3.31)
0.836 0.67 (0.22–
2.10)
0.471
A2 107 34.2 0.402 1.26 (0.73–
2.19)
0.405 45.8 0.048 1.69 (0.99–
2.89)
0.053 1.59 (0.90–
2.78)
0.108
A3 66 29.1 28.3
Gender male 82 40.4 0.016 1.82 (1.11–
2.98)
0.018 1.36 (0.79–
2.34)
0.266 49.9 0.007 1.91 (1.18–
3.07)
0.008 1.63 (0.97–
2.75)
0.067
female 101 26.9 29.7
Maximal
disease extent
E1 23 11.7 0.0 3.09 (2.0–
4.77)
< 0.001 3.15 (1.95–
5.10)
< 0.001
E2 97 28.6 0.094 3.21 (0.77–
13.43)
0.111 5.22 (0.71–
38.47)
0.105 29.3 0.013
E3 60 48.4 0.002 6.66 (1.60–
27.80)
0.009 11.67 (1.59–
85.56)
0.016 61.7 < 0.001
Smoking no 164 31.8 36.1
yes 19 33.4 0.732 1.14 (0.54–
2.40)
0.734 57.9 0.274 1.45 (0.74–
2.84)
0.276
Serologic
antibodies
Anti-CUZD1
( rPAg1) IgG
no 163 28.8 36.2
yes 11 78.6 0.031 2.34 (1.05–
5.23)
0.038 2.04 (0.91–
4.56)
0.083 78.1 0.008 2.55 (1.25–
5.20)
0.01 1.50 (0.68–
3.28)
0.316
Anti-CUZD1
( rPAg1) IgA
no 162 29.7 36.8
yes 12 63.6 0.068 2.16 (0.91–
5.10)
0.077 84.1 0.005 2.78 (1.31–
5.89)
0.007 1.51 (0.69–
3.32)
0.671
ASCA IgG no 163 30.3 37.4
yes 20 55.0 0.186 1.60 (0.79–
3.27)
0.193 46.2 0.313 1.43 (0.71–
2.90)
0.315
ASCA IgA no 163 31.0 34.7
yes 20 50.0 0.158 1.65 (0.81–
3.36)
0.165 64.2 0.003 2.43 (1.33–
4.46)
0.004 2.51 (1.33–
4.74)
0.005
Number of Abs
positivity (Either)
2 120 24.3 29.4
3 49 50.2 0.016 1.93 (1.11–
3.35)
0.019 2.03 (1.16–
3.56)
0.013 63.3 0.0001 2.62 (1.57–
4.38)
0.0002 3.19 (1.84–
5.53)
0.00004
Rows corresponding to atypical P-ANCA, anti-LFS antibodies, anti-goblet antibodies, anti-GP2 antibodies, and anti-OMP antibodies were omitted because statistically
significant differences for a given parameter were not obtained; significant associations are indicated in bold [p-values, hazard ratio, and 95% confidence intervals]. Data
regarding colectomy is presented in the Supplementary Material (S1 Table).
 CP (cumulative probability) of event (%) corresponds to the median follow-up values
ASCA: anti-Saccharomyces cerevisiae antibody, LFS: lactoferrin, CUZD1: CUB and zona pellucida-like domains 1,GP2: glycoprotein 2, P-ANCA: perinuclear anti-
neutrophil cytoplasmic antibodies, GCS: glycocorticosteroid
Disease extent: E1: proctitis, E2: left-sided colitis, E3: extensive colitis. Age: A1: 16 years, A2: 17–40 years, A3: > 40 years
https://doi.org/10.1371/journal.pone.0194166.t005
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HRASCAIgA: 1.65 [95% CI: 0.81–3.36]; p = 0.165). On the contrary, presence of IgA, but not the
IgG type ASCA was associated with an increased cumulative probability of the need for long-
term immunosuppressant therapy with AZA (64.2% vs. 34.7%, pLogRank = 0.003) (Fig 1). In
case of high ASCA IgA antibody titer (47 U; HRASCAIgA: 3.55 [95% CI: 1.53–8.25]; p = 0.003)
the risk of need for long-term immunosuppressant therapy was similar to those observed at
lower positive titer (25 U; HRASCAIgA: 2.43 [95% CI: 1.33–4.46]; p = 0.004). However only
the presence of IgG type ASCA was moderately associated with need of colectomy (13.6% vs.
3.8%, pLogRank = 0.014).
As for IgA or IgG type atypical P-ANCA, anti-LFS, GAB or IgA type anti-OMP antibodies,
no differences between antibody positive and negative patients were observed in terms of
either the study-endpoint events (Table 5).
Covariates. Analysis of clinical factors associated with UC-related hospitalization and
requirement for long-term immunosuppressant therapy with azathioprine using Kaplan-
Meier and univariate Cox-regression analysis is shown in Table 5. Colitis extent (Fig 1) and
male gender but neither age of onset nor smoking habits were significantly associated with
these study endpoints.
None of the clinical factors were significantly associated with need for colectomy (S1
Table).
Lastly, development of extensive disease was also considered as an unfavorable outcome. In
patient presenting with disease location E1 or E2 (n = 134) none of the examined serologic
antibodies were associated with a change to a more extended disease (E3 according to Mon-
treal classification) (S2 Table).
Multivariate analysis. Cox-regression analysis and the backward elimination procedure,
taking serologic antibodies and all clinical covariates into account, indicated that out of the
serologic markers, the presence of IgA type ASCA was independently associated with the
higher risk of need for long-term immunosuppressant therapy with AZA (HR: 2.51, 95%CI:
1.33–4.74, p = 0.005). None of the serologic antibodies were independently associated with the
higher risk of the UC-related hospitalization (Table 5).
From the clinical parameters, extensive colitis was associated with a higher risk of UC-
related hospitalization (HR: 11.67, 95%CI: 1.59–85.56, p = 0.016), and the need for long-term
immunosuppressant therapy with AZA (HR: 3.15, 95%CI: 1.95–5.10, p<0.001) (Table 5).
Evaluation of multiple positivity for different antibodies was performed; co-existence of
three or more different types of antibodies was associated with UC-related hospitalization
along with long-term immunosuppressant therapy but not associated with development of
extensive disease or need for colectomy in univariate and multivariate time dependent analysis
as well. These result appeared to be superior to single antibody positivity in these unfavorable
disease outcomes (Table 5).
Discussion
In the present study, we investigated the clinical importance of an extensive panel of serologic
antibodies comprising both classic and newly discovered auto- and anti-microbial antibodies
in the prediction of the long-term disease course in adult UC patients. To our knowledge, this
is the largest prospective referral cohort to date, which has been examined by such a wide
range of serologic antibodies.
In our cohort, the seropositivity rate of classic serologic antibodies, namely atypical
P-ANCA and ASCA, and also anti-OMP antibody corresponds to those previously reported in
UC (45–82%, 5–15%, and 20–24%, respectively) [1]. It should be noted, however, that IgA
type anti-OMP antibody examined in the present study is clearly different from anti-OmpC.
UC serology
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Fig 1. Kaplan–Meier survival plot of need for long-term immunosuppressant therapy with azathioprine in
ulcerative colitis during follow-up.
https://doi.org/10.1371/journal.pone.0194166.g001
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Similar prevalence rate of anti-OmpC (5–28%) [1] and resemblance in nomenclature some-
times causes confusion in the literature. Anti-OMP antibody is directed against multiple bacte-
rial proteins derived from two species of intestinal bacteria (one gram positive and one gram
negative). Neither bacteria are from the phylum proteobacteria, of which Escherichia coli is a
member. At the same time, anti-OmpC antibody is specifically directed to the outer membrane
protein C transport protein of Escherichia coli. Fewer data are available regarding the preva-
lence of target specific PABs (anti-GP2 and anti-CUZD1) in patients with UC. In the largest
study assessing UC patients (n = 136), both the anti-GP2 and the anti-CUZD1 seropositivity
rates were low, 2.9% and 5.9%, respectively, similar to our findings [27].
Prognostic value of serologic antibodies relies on documentation of their stability over
time. Accordingly, in the present study we extensively assessed the long-term stability of vari-
ous antibodies. We found the status of serologic antibodies was not associated with actual dis-
ease activity, and positivity rates were stable over time. Most studies in UC that have measured
antibodies during active and inactive disease have shown no correlation between P-ANCA
and disease severity [8]. Regarding antibody stability, in a previous study of Vecchi et al.[12]
atypical p-ANCA IgG status remained constant over time (50.8 month time period) when eval-
uated at more than one time point in a small cohort of UC patients (n = 40). Change in anti-
body status occurred in 25% of patients, similar to our findings. In our cohort changes of IgG
subtype of atypical p-ANCA was 14.4%, while IgA subtype was 23.2%. ASCA and other sero-
logic antibodies showed even lower variation ( 10% of cases). This is consistent with previous
data provided by Rieder et al. [28]. Anti-glycan antibody (such as ASCA) status remained
unchanged from the status determined at the initial sample procurement in the vast majority
of UC and CD patients. The median time between sample procurements, however, was rela-
tively short (6.2 months).
Reports regarding association of serologic markers with long-term disease course in UC
have generally been restricted to the evaluation of atypical P-ANCA and ASCA. Newly identi-
fied antibodies have not been well studied in this clinical setting. Possible differences according
to antibody subtypes (IgA or IgG type) have also not been within the scope of these studies.
Our previous findings that IgA, but not IgG types of PAbs, were associated with complicated
disease course in patients with CD support this latter approach [15]. In the present study we
aimed to fill these gaps.
In previous longitudinal clinical studies, association between serologic antibodies and
adverse disease outcome yielded somewhat discordant results, for various reasons. From the
clinical point of view, unfavorable disease outcome—beyond colectomy—was not defined in
a unified manner in these studies. In addition, study populations were different as well as
regarding the sample size, study design (referral or population-based patient cohort) or fol-
low-up time. It is known that the proportion of IBD patients developing an unfavorable disease
outcome could be significantly different in referral and population-based cohorts [29]. Like-
wise reported prevalences of serologic antibodies are lower in population-based cohorts [11].
In the present study, four primary end-points were selected to define unfavorable disease
outcome in UC: development of extensive disease, need for colectomy, requirement for one or
more UC-related hospitalization due to disease activity and need for long-term immunosup-
pressant therapy with AZA.
A change to a more extended disease (E3 according to Montreal classification) can be con-
sidered as an unfavorable disease outcome worth to evaluate, however only limited data is
available in the literature regarding proximal disease progression over time, as well as the
related factors, especially serologic markers having an impact on this outcome. The majority of
studies were conducted on this matter more than 20 years ago [30–34].Rate of disease extent
progression reported previously varies from 15% to 53% depending on disease duration at the
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end of follow-up time (5, 10 and 25 years) [30–43]. Until now, the most thorough over time
extent evaluation was presented in a Swiss IBD Cohort Study (n = 918), where 9.48% of UC
patients (E1 or E2) developed E3 disease during follow up (median time: 9 years) [41]. We
found similar progression rate to an extensive disease (n = 134) in our UC patients (12.7%)
with similar median follow up time (8.6 years). The strength of our study is that we analyzed
for the first time, whether the presence or absence of the classic and novel antibodies are asso-
ciated with a shorter time to development of an extensive disease, however we failed to prove
any significant association. Although, the lack of prognostic potential of these antibodies in
this particular outcome should be interpreted cautiously due to low event and patient numbers
in antibody positive groups. Former small-scale referral cohort studies demonstrated [12, 44,
45] that the presence of P-ANCA was associated with the need for colectomy in UC. However,
more recent large-scale studies, either in the population-based [11, 13] or referral [9, 10, 46]
cohorts, have not been able to confirm these early reports. Two population-based studies (Nor-
wegian IBSEN study [13], n = 357 and EC-IBD multicenter study[11], n = 432) did not dem-
onstrate increased risk of colectomy in the presence of P-ANCA or ASCA seropositivity [13].
Two additional referral cohort studies from Canada [9, 10] further confirmed the lack of asso-
ciation between serologic antibodies and need for colectomy. Beyond P-ANCA and ASCA
seropositivity, other serologic antibodies, such as anti-OmpC or CBir1 [9], were also not asso-
ciated with the risk of colectomy. Only one single study [14] found that anti-OmpC positivity
was associated to the requirement for colectomy. In the present referral cohort study, we also
did not find clinically relevant associations between the requirement for colectomy and the
presence of either the classic or the newly identified serologic antibodies, including anti-OMP.
The anti-OMP assay used in current study is significantly different from anti-OmpC assay, as
previously mentioned.
Concerning UC-related hospitalization as an unfavorable diseases outcome, no significant
association was found with P-ANCA and ASCA seropositivity in a recent large-scale referral
cohort study of Kevans et al.[9](n = 230). Colitis extent was the single variable of the clinical
factors that associated with the study endpoint (HR 2.7, 95%CI: 1.5–4.6, p = 0.006). In agree-
ment with that study, only the disease extent, and not any of the serologic antibodies, was able
to predict UC-related hospitalization (HR 11.7, 95%CI: 1.6–85.6, p = 0.016) in our cohort.
Requirement for, or response to, certain medical therapies as an adverse outcome in UC
was also evaluated in former studies. Mainly corticosteroid or biological therapy was assessed
either individually [9] or in combination as components of prognostic profile groups describ-
ing disease severity [10]. The need for more intense treatment with AZA was assessed in a sin-
gle study of Soleberg et al.[13]). P-ANCA positive patients had about 4-fold higher risk of
receiving AZA treatment during follow up (OR: 4.14, 95%CI: 1.73–9.82, p = 0.005). However,
in our study, ASCA, and not the P-ANCA seropositivity was associated with a more active
course of UC, as there was a significant relationship between presence of ASCA and the overall
use of AZA. Interestingly, only IgA, but not IgG type of antibody showed this link. Gut muco-
sal immune system plays a central role in the IgA antibody formation, and this may at least
partly reflect an immune response against an overwhelming microbial challenge. In addition,
IgA type autoantibodies are considered as a sign of immunological response to enteric antigens
in other diseases associated with enhanced bacterial translocation. Our group reported that
IgA type antibodies have a pivotal role in the development of disease-specific complications
compared with the IgG antibody subtype [47]. Remarkably, in the present cohort the occur-
rence of IgA type target specific PAbs but not IgG type was significantly higher in those
patients with concomitant PSC. The same association was reported previously [15] in a cohort
of our CD patients. That was confirmed later by Michaels et al. [27] in UC and CD as well.
UC serology
PLOS ONE | https://doi.org/10.1371/journal.pone.0194166 March 28, 2018 13 / 18
These findings might serve as an additional hint towards the importance of gut mucosal
immune system dysfunction in the development of hepatobiliary manifestations [48].
Based on the experience gained from previous serological studies in IBD [1] including
those performed by us as well, we know that an increasing number or magnitude of seroposi-
tivity can yield higher association with disease complications than single markers. In the pres-
ent study, however we were not able to confirm that the use of highest quartiles as cut-off
values were superior compared to the original ones. Although, we have to highlight that the
lack of associations regarding highest antibody titers can be the result of a very limited number
of patients belonging to these categories. Distinctly, multiple seropositivity, namely the co-
existence of three or more different types of antibodies, results proved to be superior compared
to single antibody positivity regarding certain outcomes, such as UC-related hospitalization
and need for long-term immunosuppressant therapy.
This study has some limitations: (1) our hospital is a regional referral center for IBD
patients introducing a selection bias; (2) relatively small number of subjects underwent colect-
omy but it is in accordance with previous reports from Eastern Europe [49]; thus any lack of
significant association could also be explained by insufficient statistical power (type 2 error);
(3) the wide range of seropositivity of the examined antibody panel (9–73%) did not make
possible an equally powered evaluation in case of each certain markers and warrants further
validation in larger patient cohort. (4) our patient cohort is followed prospectively and the
database is updated regularly for that concern. Serum sampling, however, occurred later in
subject’s disease course rather than at or soon after diagnosis. Median disease duration was 4
years at serum drawing which is a significantly shorter interval than in previous studies. At the
same time, sufficient prospective follow-up (median, 11 years) was available after sampling.
Seventy-six percent of our patients had at least 5 years of follow-up which is the period sug-
gested by Silverberg et al.[10] that is required for evaluation of long-term outcomes. Based on
these and the stability data of the present study, we believe that our serologic findings provide
reliable prognostic information for the whole disease course of UC, including near the time of
the diagnosis as well.
In conclusion, consistent with the majority of previous reports, we have shown that pres-
ence of atypical P-ANCA is not associated with unfavorable disease outcome in UC. We did
not demonstrate any association of newly identified serologic antibodies with the unfavorable
disease outcome. We demonstrated, however, a novel association between the presence of IgA,
but not the IgG type ASCA and requirement for long-term immunosuppressant therapy with
AZA. Assessment of serologic antibody subtypes may prove to be an important novel parame-
ter. Further studies are now needed to validate and extend these results.
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